End-stage renal disease in 2010: Innovative approaches to improve outcomes in transplantation

Nature Reviews Nephrology

Volumn 7, Issue 2, 2011, Pages 68-70

  Shapiro, Ron ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BELATACEPT; BORTEZOMIB; CYCLOSPORIN A; ECULIZUMAB; HEMOGLOBIN; IMMUNOSUPPRESSIVE AGENT; LIM 0705; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; UNCLASSIFIED DRUG;

CHRONIC KIDNEY DISEASE; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STEROID THERAPY;

GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; TREATMENT OUTCOME;

EID: 79551567119     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2010.179     Document Type: Review

References (10)

1. Vincenti, F. et al. A phase III study of belataceptbased immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am. J. Transplant. 10, 536-546 (2010).
2. Durrbach, A. et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENIFIT-EXT study). Am. J. Transplant. 10, 547-557 (2010).
3. Walsh, R. C. et al. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation 89, 277-284 (2010).
4. Sberro-Soussan, R. et al. Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies. Am. J. Transplant. 10, 681-686 (2010).
5. Salgo, R. et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-) maglignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded controlled clinical trial. Am. J. Transplant. 10, 1385-1395 (2010).
6. Poommipanit, N. et al. Pancreas after living donor kidney versus simultaneous pancreaskidney transplant: an analysis of the organ procurement transplant network/united network of organ sharing database. Transplantation 89, 277-284 (2010).
7. Stegall, M. D. et al. Terminal complement inhibition decreases early acute humoral rejection in sensitized renal transplant recipients [abstract 1]. Am. J. Transplant. 10, 39(2010).
8. Robbins, W. R., Schmidt, W. K. & Lee, V. J. LIM-0705, an activator of specific ABC transporters, prevents and treats tacrolimusinduced hyperglycemia in the rat [abstract 148]. Am. J. Transplant. 10, 84(2010).
9. Robbins, W. R. et al. LIM-0705 activates specific ABC transporters allowing efflux of tacrolimus out of rat kidney and pancreas that may help ameliorate toxicity [abstract 149]. Am. J. Transplant. 10, 84(2010).
10. Robbins, W. R. et al. LIM-0705 an activator of specific ABC transporters, prevents and treats tacrolimus-induced renal tubular vacuolization in a rat model [abstract 150]. Am. J. Transplant. 10, 85(2010).